Previous studies have shown that activated PXR and CAR worsen the hepatic steatosis and insulin resistance in NAFLD by suppressing gluconeogenesis and β-oxidation and increasing hepatic fatty acids uptake (131, 132). Here, NR1I2 is linked to metabolic dysfunction-associated steatotic liver disease.